Do analysts rate RPRX or RDY?

Royalty Pharma currently has a consensus target price of $60.86, suggesting a potential downside of 0.90%. Given Royalty Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Royalty Pharma is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Royalty Pharma 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Dr. Reddy's Laboratories 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media refer more to RPRX or RDY?

In the previous week, Royalty Pharma had 5 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 9 mentions for Royalty Pharma and 4 mentions for Dr. Reddy's Laboratories. Royalty Pharma's average media sentiment score of 0.80 beat Dr. Reddy's Laboratories' score of 0.59 indicating that Royalty Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RDY or ZTS?

Zoetis has a consensus target price of $107.43, indicating a potential upside of 39.54%. Given Zoetis' stronger consensus rating and higher probable upside, analysts clearly believe Zoetis is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Zoetis 2 Sell rating(s) 9 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.32

Does the media prefer RDY or ZTS?

In the previous week, Zoetis had 14 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 18 mentions for Zoetis and 4 mentions for Dr. Reddy's Laboratories. Zoetis' average media sentiment score of 1.48 beat Dr. Reddy's Laboratories' score of 0.59 indicating that Zoetis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zoetis 16 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate VTRS or RDY?

Viatris currently has a consensus target price of $17.50, suggesting a potential upside of 6.00%. Given Viatris' stronger consensus rating and higher probable upside, analysts plainly believe Viatris is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viatris 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57 Dr. Reddy's Laboratories 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media prefer VTRS or RDY?

In the previous week, Dr. Reddy's Laboratories had 2 more articles in the media than Viatris. MarketBeat recorded 4 mentions for Dr. Reddy's Laboratories and 2 mentions for Viatris. Viatris' average media sentiment score of 1.15 beat Dr. Reddy's Laboratories' score of 0.59 indicating that Viatris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate RDY or JAZZ?

Jazz Pharmaceuticals has a consensus price target of $285.44, indicating a potential upside of 13.87%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Jazz Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 16 Buy rating(s) 1 Strong Buy rating(s) 3.00

Does the media refer more to RDY or JAZZ?

In the previous week, Jazz Pharmaceuticals had 41 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 45 mentions for Jazz Pharmaceuticals and 4 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.59 beat Jazz Pharmaceuticals' score of 0.34 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 12 Very Positive mention(s) 9 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer RDY or NBIX?

Neurocrine Biosciences has a consensus target price of $200.86, suggesting a potential upside of 30.41%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Neurocrine Biosciences is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Neurocrine Biosciences 0 Sell rating(s) 4 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.88

Does the media favor RDY or NBIX?

In the previous week, Neurocrine Biosciences had 18 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 22 mentions for Neurocrine Biosciences and 4 mentions for Dr. Reddy's Laboratories. Neurocrine Biosciences' average media sentiment score of 1.37 beat Dr. Reddy's Laboratories' score of 0.59 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 18 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Dr. Reddy's Laboratories (RDY) Competitors

$12.15 -0.03 (-0.25%)

As of 08/31/2026 03:58 PM Eastern

Compare

RDY vs. RPRX, ZTS, VTRS, JAZZ, and NBIX

Should you buy Dr. Reddy's Laboratories stock or one of its competitors? Dr. Reddy's Laboratories's main competitors and comparable companies include Royalty Pharma (RPRX), Zoetis (ZTS), Viatris (VTRS), Jazz Pharmaceuticals (JAZZ), and Neurocrine Biosciences (NBIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Dr. Reddy's Laboratories compare to Royalty Pharma?

Royalty Pharma (NASDAQ:RPRX) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

54.4% of Royalty Pharma shares are held by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 18.8% of Royalty Pharma shares are held by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Royalty Pharma currently has a consensus target price of $60.86, suggesting a potential downside of 0.90%. Given Royalty Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Royalty Pharma is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Royalty Pharma had 5 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 9 mentions for Royalty Pharma and 4 mentions for Dr. Reddy's Laboratories. Royalty Pharma's average media sentiment score of 0.80 beat Dr. Reddy's Laboratories' score of 0.59 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Royalty Pharma has higher earnings, but lower revenue than Dr. Reddy's Laboratories. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.38B	14.85	$770.95M	$1.45	42.35
Dr. Reddy's Laboratories	$3.58B	2.83	$456M	$0.44	27.61

Royalty Pharma has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

Royalty Pharma has a net margin of 32.14% compared to Dr. Reddy's Laboratories' net margin of 10.15%. Royalty Pharma's return on equity of 30.01% beat Dr. Reddy's Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	32.14%	30.01%	14.91%
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%

Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.5%. Dr. Reddy's Laboratories pays an annual dividend of $0.06 per share and has a dividend yield of 0.5%. Royalty Pharma pays out 64.8% of its earnings in the form of a dividend. Dr. Reddy's Laboratories pays out 13.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Royalty Pharma has increased its dividend for 5 consecutive years. Royalty Pharma is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Royalty Pharma beats Dr. Reddy's Laboratories on 17 of the 19 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to Zoetis?

Dr. Reddy's Laboratories (NYSE:RDY) and Zoetis (NYSE:ZTS) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

Zoetis has a net margin of 27.49% compared to Dr. Reddy's Laboratories' net margin of 10.15%. Zoetis' return on equity of 74.89% beat Dr. Reddy's Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%
Zoetis	27.49%	74.89%	18.59%

Zoetis has a consensus target price of $107.43, indicating a potential upside of 39.54%. Given Zoetis' stronger consensus rating and higher probable upside, analysts clearly believe Zoetis is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Zoetis	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32

In the previous week, Zoetis had 14 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 18 mentions for Zoetis and 4 mentions for Dr. Reddy's Laboratories. Zoetis' average media sentiment score of 1.48 beat Dr. Reddy's Laboratories' score of 0.59 indicating that Zoetis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zoetis	16 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dr. Reddy's Laboratories pays an annual dividend of $0.06 per share and has a dividend yield of 0.5%. Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 2.8%. Dr. Reddy's Laboratories pays out 13.6% of its earnings in the form of a dividend. Zoetis pays out 34.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 14 consecutive years. Zoetis is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 92.8% of Zoetis shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 0.2% of Zoetis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Zoetis has higher revenue and earnings than Dr. Reddy's Laboratories. Zoetis is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	2.83	$456M	$0.44	27.61
Zoetis	$9.47B	3.36	$2.67B	$6.07	12.68

Dr. Reddy's Laboratories has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

Summary

Zoetis beats Dr. Reddy's Laboratories on 16 of the 19 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to Viatris?

Viatris (NASDAQ:VTRS) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Viatris has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

79.9% of Viatris shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 0.3% of Viatris shares are owned by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Dr. Reddy's Laboratories has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.33	-$3.51B	-$0.36	N/A
Dr. Reddy's Laboratories	$3.58B	2.83	$456M	$0.44	27.61

Viatris currently has a consensus target price of $17.50, suggesting a potential upside of 6.00%. Given Viatris' stronger consensus rating and higher probable upside, analysts plainly believe Viatris is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Viatris' net margin of -2.79%. Viatris' return on equity of 20.02% beat Dr. Reddy's Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.79%	20.02%	8.02%
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%

In the previous week, Dr. Reddy's Laboratories had 2 more articles in the media than Viatris. MarketBeat recorded 4 mentions for Dr. Reddy's Laboratories and 2 mentions for Viatris. Viatris' average media sentiment score of 1.15 beat Dr. Reddy's Laboratories' score of 0.59 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 2.9%. Dr. Reddy's Laboratories pays an annual dividend of $0.06 per share and has a dividend yield of 0.5%. Viatris pays out -133.3% of its earnings in the form of a dividend. Dr. Reddy's Laboratories pays out 13.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Viatris is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Viatris beats Dr. Reddy's Laboratories on 11 of the 18 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to Jazz Pharmaceuticals?

Dr. Reddy's Laboratories (NYSE:RDY) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Dr. Reddy's Laboratories has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

In the previous week, Jazz Pharmaceuticals had 41 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 45 mentions for Jazz Pharmaceuticals and 4 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.59 beat Jazz Pharmaceuticals' score of 0.34 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	12 Very Positive mention(s)	9 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Jazz Pharmaceuticals has a net margin of 20.45% compared to Dr. Reddy's Laboratories' net margin of 10.15%. Jazz Pharmaceuticals' return on equity of 33.97% beat Dr. Reddy's Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%
Jazz Pharmaceuticals	20.45%	33.97%	13.02%

Jazz Pharmaceuticals has a consensus price target of $285.44, indicating a potential upside of 13.87%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	3.00

Dr. Reddy's Laboratories has higher earnings, but lower revenue than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	2.83	$456M	$0.44	27.61
Jazz Pharmaceuticals	$4.27B	3.81	-$356.15M	$14.50	17.29

Summary

Jazz Pharmaceuticals beats Dr. Reddy's Laboratories on 14 of the 17 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to Neurocrine Biosciences?

Dr. Reddy's Laboratories (NYSE:RDY) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

Neurocrine Biosciences has a net margin of 20.91% compared to Dr. Reddy's Laboratories' net margin of 10.15%. Neurocrine Biosciences' return on equity of 22.43% beat Dr. Reddy's Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%
Neurocrine Biosciences	20.91%	22.43%	15.64%

Dr. Reddy's Laboratories has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Neurocrine Biosciences has a consensus target price of $200.86, suggesting a potential upside of 30.41%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Neurocrine Biosciences is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88

Neurocrine Biosciences has lower revenue, but higher earnings than Dr. Reddy's Laboratories. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	2.83	$456M	$0.44	27.61
Neurocrine Biosciences	$2.86B	5.47	$478.60M	$6.82	22.59

In the previous week, Neurocrine Biosciences had 18 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 22 mentions for Neurocrine Biosciences and 4 mentions for Dr. Reddy's Laboratories. Neurocrine Biosciences' average media sentiment score of 1.37 beat Dr. Reddy's Laboratories' score of 0.59 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurocrine Biosciences	18 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Neurocrine Biosciences beats Dr. Reddy's Laboratories on 15 of the 17 factors compared between the two stocks.

Get Dr. Reddy's Laboratories News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RDY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RDY vs. The Competition

Export

Metric	Dr. Reddy's Laboratories	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$10.17B	$12.19B	$7.20B	$24.17B
Dividend Yield	0.53%	2.62%	2.54%	3.72%
P/E Ratio	27.61	785.16	272.59	29.84
Price / Sales	2.83	755.91	624.07	20.70
Price / Cash	14.38	15.32	28.74	19.75
Price / Book	2.50	10.48	11.05	4.82
Net Income	$456M	$2.83B	$3.47B	$1.07B
7 Day Performance	-0.53%	0.23%	1.28%	-0.89%
1 Month Performance	2.57%	5.33%	8.29%	1.56%
1 Year Performance	-14.41%	6.01%	24.29%	12.92%

Dr. Reddy's Laboratories Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RDY Dr. Reddy's Laboratories	1.7775 of 5 stars	$12.15 -0.2%	N/A	-14.4%	$10.17B	$3.58B	27.61	27,527	Analyst Upgrade
RPRX Royalty Pharma	3.955 of 5 stars	$62.08 +0.5%	$60.86 -2.0%	+70.7%	$35.67B	$2.54B	42.79	80	Analyst Downgrade
ZTS Zoetis	4.937 of 5 stars	$75.30 -2.9%	$107.43 +42.7%	-50.8%	$31.14B	$9.53B	12.42	14,500	Positive News
VTRS Viatris	2.8122 of 5 stars	$16.95 +0.6%	$17.50 +3.3%	+56.5%	$19.46B	$14.74B	N/A	30,000	Analyst Upgrade
JAZZ Jazz Pharmaceuticals	3.985 of 5 stars	$248.46 -0.3%	$279.00 +12.3%	+96.2%	$16.11B	$4.27B	17.11	2,890	Positive News Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:RDY) was last updated on 9/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dr. Reddy's Laboratories (RDY) Competitors

RDY vs. RPRX, ZTS, VTRS, JAZZ, and NBIX

How does Dr. Reddy's Laboratories compare to Royalty Pharma?

Summary

How does Dr. Reddy's Laboratories compare to Zoetis?

Summary

How does Dr. Reddy's Laboratories compare to Viatris?

Summary

How does Dr. Reddy's Laboratories compare to Jazz Pharmaceuticals?

Summary

How does Dr. Reddy's Laboratories compare to Neurocrine Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDY vs. The Competition

Dr. Reddy's Laboratories Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dr. Reddy's Laboratories (RDY) Competitors

RDY vs. RPRX, ZTS, VTRS, JAZZ, and NBIX

How does Dr. Reddy's Laboratories compare to Royalty Pharma?

Do institutionals and insiders believe in RPRX or RDY?

Do analysts rate RPRX or RDY?

Does the media refer more to RPRX or RDY?

Which has preferable earnings & valuation, RPRX or RDY?

Which has more risk & volatility, RPRX or RDY?

Is RPRX or RDY more profitable?

Is RPRX or RDY a better dividend stock?

Summary

How does Dr. Reddy's Laboratories compare to Zoetis?

Is RDY or ZTS more profitable?

Do analysts prefer RDY or ZTS?

Does the media prefer RDY or ZTS?

Is RDY or ZTS a better dividend stock?

Do institutionals & insiders have more ownership in RDY or ZTS?

Which has higher earnings and valuation, RDY or ZTS?

Which has more volatility and risk, RDY or ZTS?

Summary

How does Dr. Reddy's Laboratories compare to Viatris?

Which has more risk and volatility, VTRS or RDY?

Do insiders and institutionals believe in VTRS or RDY?

Which has stronger valuation & earnings, VTRS or RDY?

Do analysts rate VTRS or RDY?

Is VTRS or RDY more profitable?

Does the media prefer VTRS or RDY?

Is VTRS or RDY a better dividend stock?

Summary

How does Dr. Reddy's Laboratories compare to Jazz Pharmaceuticals?

Which has more volatility and risk, RDY or JAZZ?

Does the media refer more to RDY or JAZZ?

Do insiders and institutionals hold more shares of RDY or JAZZ?

Is RDY or JAZZ more profitable?

Do analysts rate RDY or JAZZ?

Which has better valuation and earnings, RDY or JAZZ?

Summary

How does Dr. Reddy's Laboratories compare to Neurocrine Biosciences?

Is RDY or NBIX more profitable?

Which has more risk and volatility, RDY or NBIX?

Do insiders and institutionals have more ownership in RDY or NBIX?

Do analysts prefer RDY or NBIX?

Which has better valuation & earnings, RDY or NBIX?

Does the media favor RDY or NBIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDY vs. The Competition

Dr. Reddy's Laboratories Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools